Vir Biotechnology, Inc. (VIR)
| Market Cap | 1.83B +152.2% |
| Revenue (ttm) | 303.23M +1,495.9% |
| Net Income | -251.68M |
| EPS | -1.70 |
| Shares Out | 169.22M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,835,139 |
| Open | 11.16 |
| Previous Close | 11.31 |
| Day's Range | 10.80 - 11.46 |
| 52-Week Range | 4.75 - 11.66 |
| Beta | 1.59 |
| Analysts | Strong Buy |
| Price Target | 21.00 (+93.91%) |
| Earnings Date | Aug 5, 2026 |
About VIR
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company’s preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting va... [Read more]
Financial Performance
In 2025, Vir Biotechnology's revenue was $68.56 million, a decrease of -7.61% compared to the previous year's $74.21 million. Losses were -$437.99 million, -16.09% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for VIR stock is "Strong Buy." The 12-month stock price target is $21.0, which is an increase of 93.91% from the latest price.
News
Vir Biotechnology price target lowered to $25 from $27 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Vir Biotechnology (VIR) to $25 from $27 and keeps an Overweight rating on the shares after the company reported Q2 financials and…
Vir Biotechnology price target lowered to $19 from $21 at Leerink
Leerink analyst Roanna Ruiz lowered the firm’s price target on Vir Biotechnology (VIR) to $19 from $21 and keeps an Outperform rating on the shares.
Vir Biotechnology reports Q2 EPS 47c vs. (80c) last year
Reports Q2 revenue $238.9M, consensus $225.57M. Based on its current operating plans, including the net effects of the Astellas global collaboration, the company expects its cash, cash equivalents and...
Vir Biotechnology Earnings Call Transcript: Q2 2026
Strong Q2 2026 results driven by major collaboration revenue and robust clinical progress in hepatitis delta and oncology. Cash position improved to $1.01 billion, supporting a runway into 2028. Key clinical milestones are on track, with best-in-class efficacy data and commercial readiness advancing.
Vir Biotechnology Slides: Q2 2026
Vir Biotechnology has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Vir Biotechnology Earnings release: Q2 2026
Vir Biotechnology released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Vir Biotechnology Quarterly report: Q2 2026
Vir Biotechnology has published its Q2 2026 quarterly earnings report on August 5, 2026.
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2026. “This is a pivotal t...
Vir Biotechnology CFO Jason O’Byrne to depart
Vir Biotechnology (VIR) announced that Brent Sabatini, SVP and Chief Accounting Officer, has been appointed Interim Principal Financial Officer. Jason O’Byrne is leaving the Company to pursue another ...
Vir Biotechnology Announces Chief Financial Officer Transition
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Fina...
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate u...
Vir Biotechnology price target raised to $27 from $23 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Vir Biotechnology (VIR) to $27 from $23 and keeps an Overweight rating on the shares. Hepatitis delta virus remains underdiagnosed and recent…
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June ...
Vir Biotechnology Transcript: AGM 2026
The meeting introduced board and executive changes, presented three shareholder proposals, and confirmed the election of directors, approval of executive compensation, and auditor ratification. Voting outcomes will be formally reported to the SEC.
Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial
Vir Biotechnology (VIR) “announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL...
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsir...
Vir Biotechnology Transcript: Bank of America Global Healthcare Conference 2026
Multiple value creation paths are advancing, including a near-term Delta Program, a differentiated oncology platform, and a robust HDV regimen outperforming competitors. Strategic partnerships and a strong cash position support parallel development and targeted commercial build-out.
Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Vir Biotechnology (VIR) to $23 from $24 and keeps an Overweight rating on the shares.
Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year
“Vir Bio delivered incredible momentum during the first quarter with positive, new VIR-5500 Phase 1 data and execution of a global agreement with Astellas in prostate cancer. The closing of…
Vir Biotechnology Earnings Call Transcript: Q1 2026
Major advances in oncology and hepatitis delta programs, highlighted by a $1.7B Astellas collaboration and strong phase II data for tobevibart plus elebsiran. Cash runway extends into 2H 2028, supporting multiple milestones and disciplined capital allocation.
Vir Biotechnology Earnings release: Q1 2026
Vir Biotechnology released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Vir Biotechnology Slides: Q1 2026
Vir Biotechnology has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Vir Biotechnology Quarterly report: Q1 2026
Vir Biotechnology has published its Q1 2026 quarterly earnings report on May 6, 2026.
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2026. “Vir Bio delivered i...
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the B...